Study in Healthy Volunteers and COPD Patients to Evaluate the Efficacy and Safety of Inhaled TV46017

Teva Pharmaceuticals

Status and phase

Terminated

Phase 1

Conditions

Chronic Obstructive Pulmonary Disease (COPD

Treatments

Drug: Placebo

Drug: TV46017

Study type

Interventional

Funder types

Industry

Identifiers

NCT02315131

TV46017-COPD-10046

Details and patient eligibility

About

The primary objective of the study is to characterize the safety profile and duration of bronchodilation of a single dose of inhaled TV46017

Enrollment

53 patients

Sex

All

Ages

20 to 75 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Stage 1 Inclusion Criteria (healthy volunteers):

The subject is a male or female 20 to 75 years of age, inclusive, weighing 50 to 80 kg with a body mass index (BMI) of less than 30 kg/m2. Note: Every effort should be made to enroll approximately equal numbers of men and women in each group.
The subject is in good health as determined by medical and psychiatric history, physical examination, electrocardiogram (ECG), serum chemistry, hematology, urinalysis, and serology.
Other criteria apply, please contact the investigator for more information

Stage 2 Inclusion Criteria (COPD patients):

Current or former cigarette smokers with a history of cigarette smoking of ≥10 pack years at the SV (number of cigarette packs smoked per day multiplied by the number of years smoked; eg, 2 packs/day for 3 years equals a 6 pack year history).
Diagnosis of COPD as defined by the Global Initiative for Chronic Obstructive Lung Disease guidelines.
Male or female; 40 to 75 years of age, inclusive.
Patient is free of any other medical conditions or concomitant treatment that could interfere with study conduct, influence the interpretation of study observations/results, or put the patient at increased risk during the study.
Other criteria apply, please contact the investigator for more information

Stage 1 Exclusion Criteria (healthy volunteers):

History or current evidence of a clinically significant or uncontrolled disease.
Any disorder that may interfere with the absorption, distribution, metabolism or excretion of study drugs.
History of severe allergy to milk protein.
Active smokers or former smokers who quit within 3 months of the first dose of study drug. Former smokers with greater than five-pack years (ie, the equivalent of one pack per day for five years) are also excluded.
Other criteria apply, please contact the investigator for more information

Stage 2 Exclusion Criteria (COPD patients):

Recent history of hospitalization due to an exacerbation of airway disease within 3 months.
Need for increased treatments of COPD within 6 weeks prior to the SV.
Occurrence of a COPD exacerbation, which is not resolved by 4 weeks or more prior to the SV/informed consent. (Note: An exacerbation of COPD is defined as any worsening of the patient's baseline COPD symptoms requiring any treatment other than rescue albuterol or the patient's regular maintenance therapy. This includes requiring the use of systemic corticosteroids, antibiotics, and/or emergency room visit or hospitalization.)
History of and/or current diagnosis of asthma.
Known α1 antitrypsin deficiency, active lung infections (such as tuberculosis or pneumonia), and lung cancer are absolute exclusionary conditions. A patient who, in the opinion of the investigator, has any other significant respiratory condition in addition to COPD should be excluded. Examples may include clinically significant noncystic bronchiectasis, pulmonary hypertension, sarcoidosis, or interstitial lung disease. Allergic rhinitis is not exclusionary.
Other criteria apply, please contact the investigator for more information

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

53 participants in 6 patient groups, including a placebo group

TV46017- Healthy Volunteers

Experimental group

Description:

Stage 1 includes a single-dose treatment period

Treatment:

Drug: TV46017

Placebo - Healthy Volunteers

Placebo Comparator group

Description:

Some healthy subjects will be randomized to receive placebo.

Treatment:

Drug: Placebo

TV46017 15 μg- COPD

Experimental group

Description:

Stage 2 includes two 24 hour treatment periods with approximately 7 days of washout in between each treatment period; and open label ipratropium bromide pressurized metered-dose inhaler hydrofluoroalkane (HFA) will be administered

Treatment:

Drug: TV46017

TV46017 60 μg- COPD

Experimental group

Description:

Stage 2

Treatment:

Drug: TV46017

TV46017 120 μg- COPD

Experimental group

Description:

Stage 2